Vertex Reports Third-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Vertex Pharma (VRTX) Tops Q3 EPS by 8c; Offers FY19 Revenue Outlook
October 30, 2019 4:08 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $1.23, $0.08 better than the analyst estimate of $1.15. Revenue for the quarter came in at $950 million versus the consensus estimate of $950.9 million.
"2019 has been a year of significant progress for Vertex across all parts of our... More
